Decoding the Research Landscape of Drug Resistance and Therapeutic Approaches in Head and Neck Cancer: a Bibliometric Analysis from 2000 to 2023

Overview

Journal Front Pharmacol

Date 2024 Apr 22

PMID 38645557

Authors

Qi Han

Junqi Shi

Jiaojiao Liu

Yang Fu

Zhongxun Li

Huina Guo

Xiaoya Guan

Xuting Xue

Hongliang Liu

Liting Zhao

Chunming Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Head and neck cancer is one of the most common tumors worldwide. However, drug resistance in its treatment has become a major factor limiting the efficacy. This study aims to comprehensively understand the current status of research in this field.

Methods: The study analyzes papers related to therapeutic resistance in head and neck cancer published between 2000 and 2023 in the Web of Science Core Collection To achieve the research objectives, we searched the WoSCC for research and review papers on therapeutic resistance in head and neck cancer from 2000 to 2023, screened the English literature, and analyzed the research hotspots, academic collaborations, and trends in detail using tools such as Citespace, SCImago Graphica, and VOS viewer.

Results: This study summarizes 787 head and neck cancer treatment resistance publications from WoSCC. The analysis showed that China and the United States are the major contributors in this field, and Grandis Jennifer R and Yang Jai-Sing are the key scholars. Keyword analysis showed that "cisplatin resistance" is a continuing focus of attention, while "Metastasis" and "Ferroptosis" may be emerging research hotspots. Literature clustering analysis pointed out that "Ferroptosis", "Immunotherapy" and "ERK signaling" were the recent hotspots that received extensive attention and citations. Finally, we discuss the current status and challenges in drug-resistant therapies for head and neck cancer.

Conclusion: This study is the first comprehensive bibliometric analysis of drug resistance in head and neck cancer. Reveals current trends and helps researchers grasp cutting-edge hotspots in the field.

Citing Articles

Bibliometric analysis of youth myocardial infarction research (1980-2023).

Fu Y, Han Q, Wang F, Dong X Front Cardiovasc Med. 2024; 11:1478158.

PMID: 39660115 PMC: 11628501. DOI: 10.3389/fcvm.2024.1478158.

References

Shin D, Kim E, Lee J, Roh J . Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med. 2018; 129:454-462. DOI: 10.1016/j.freeradbiomed.2018.10.426. View

Chang W, Tsai C, Yang J, Hsu Y, Shih L, Chiu H . Resveratrol inhibited the metastatic behaviors of cisplatin-resistant human oral cancer cells via phosphorylation of ERK/p-38 and suppression of MMP-2/9. J Food Biochem. 2021; 45(6):e13666. DOI: 10.1111/jfbc.13666. View

Muranyi J, Duro C, Gurbi B, Mora I, Varga A, Nemeth K . Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms. Int J Mol Sci. 2023; 24(4). PMC: 9964293. DOI: 10.3390/ijms24043456. View

Chaudhary V, Chaudhary N, Mathews S, Singh R . Human Papilloma Virus-Associated Oral Pharyngeal Squamous Cell Carcinoma: Prevalence, Prevention, and Awareness of Vaccination in the Indian Population. Crit Rev Oncog. 2023; 28(2):63-72. DOI: 10.1615/CritRevOncog.2023048944. View

Doghish A, El-Mahdy H, Ismail A, Hegazy M, Mokhtar M, Elkhawaga S . Significance of miRNAs on the thyroid cancer progression and resistance to treatment with special attention to the role of cross-talk between signaling pathways. Pathol Res Pract. 2023; 243:154371. DOI: 10.1016/j.prp.2023.154371. View

Qiao X, Zhu L, Song R, Shang C, Guo Y . CD44 occurring alternative splicing promotes cisplatin resistance and evokes tumor immune response in oral squamous cell carcinoma cells. Transl Oncol. 2023; 31:101644. PMC: 9982036. DOI: 10.1016/j.tranon.2023.101644. View

Byun J, Huang K, Lee J, Huang W, Hu L, Zheng X . Targeting HIF-1α/NOTCH1 pathway eliminates CD44 cancer stem-like cell phenotypes, malignancy, and resistance to therapy in head and neck squamous cell carcinoma. Oncogene. 2022; 41(9):1352-1363. DOI: 10.1038/s41388-021-02166-w. View

Sperling G, Shatila M, Varatharajalu K, Lu Y, Altan M, Zhou Y . Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors. J Cancer Res Clin Oncol. 2023; 149(19):17597-17605. DOI: 10.1007/s00432-023-05461-z. View

Liu S, Qin Z, Mao Y, Wang N, Zhang W, Wang Y . Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma. Theranostics. 2024; 14(2):622-639. PMC: 10758066. DOI: 10.7150/thno.88759. View

10.

Yang C, Hsieh C, Lin C, Lin C, Peng B, Lin G . Danshen extract circumvents drug resistance and represses cell growth in human oral cancer cells. BMC Complement Altern Med. 2017; 17(1):555. PMC: 5747158. DOI: 10.1186/s12906-017-2063-y. View

11.

Liu Y, Chen C, Zhou Y, Zhang N, Liu S . Twenty years of research on borderline personality disorder: a scientometric analysis of hotspots, bursts, and research trends. Front Psychiatry. 2024; 15:1361535. PMC: 10941281. DOI: 10.3389/fpsyt.2024.1361535. View

12.

Trocchianesi S, Po A, Citarella A, Spinello Z, Rughetti A, Besharat Z . Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance. Biomed Pharmacother. 2023; 164:114995. DOI: 10.1016/j.biopha.2023.114995. View

13.

Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

14.

Tasaki Y, Sugiyama Y, Hamamoto S, Naiki T, Uemura T, Yokota K . Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer Med. 2023; 12(24):21666-21679. PMC: 10757154. DOI: 10.1002/cam4.6724. View

15.

Roh J, Kim E, Jang H, Shin D . Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2016; 11:254-262. PMC: 5198738. DOI: 10.1016/j.redox.2016.12.010. View

16.

Xiao L, Hu Z, Dong X, Tan Z, Li W, Tang M . Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy. Oncogene. 2014; 33(37):4568-78. PMC: 4162460. DOI: 10.1038/onc.2014.32. View

17.

Vermorken J, Guigay J, Mesia R, Trigo J, Keilholz U, Kerber A . Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer. 2011; 104(11):1691-6. PMC: 3111165. DOI: 10.1038/bjc.2011.152. View

18.

Banerjee R, Liu M, Bellile E, Schmitd L, Goto M, Hutchinson M . Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab. Mol Ther. 2021; 30(1):468-484. PMC: 8753291. DOI: 10.1016/j.ymthe.2021.06.009. View

19.

Kim J, Yun H, Um H, Park J, Lee K, Kang C . Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells. Cancer Biol Ther. 2012; 13(13):1307-18. PMC: 3493439. DOI: 10.4161/cbt.21788. View

20.

von Bohlen Und Halbach O . How to judge a book by its cover? How useful are bibliometric indices for the evaluation of "scientific quality" or "scientific productivity"?. Ann Anat. 2011; 193(3):191-6. DOI: 10.1016/j.aanat.2011.03.011. View